Ascletis Pharma Inc. Announces Initiation of U.S. Phase IIA Study for Once-Monthly Subcutaneous GLP-1R Agonist ASC30 for Obesity Treatment
Ascletis Pharma Inc. has announced the initiation of a new U.S. 12-week Phase IIa clinical study involving the dosing of the first participants with obesity or overweight who have at least one weight-related comorbidity. The study is evaluating the once-monthly subcutaneous depot formulation of ASC30, a small molecule GLP-1 receptor agonist, for the treatment of obesity. The company has indicated that topline data from this study are expected to be available in the first quarter of 2026. ASC30, discovered and developed in-house by Ascletis, is designed for both oral tablet and subcutaneous injection administrations. It is protected by U.S. and global patents until 2044, without extensions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。